Business Context and Reporting Period
BeyondSpring Inc. (BYSI) is a clinical-stage global biopharmaceutical company incorporated in the Cayman Islands. The company focuses on developing innovative cancer therapies, primarily centered on its lead asset, Plinabulin, a first-in-class microtubule modulator. The reporting period covers the fiscal year ended December 31, 2025. The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss (Continuing Operations) | $(8.7 million) | $(8.9 million) |
| Net Loss (Discontinued Operations) | $(5.5 million) | $(7.8 million) |
| Total Net Loss | $(14.2 million) | $(16.7 million) |
| Accumulated Deficit | $(408.4 million) | $(407.4 million) |
| Cash and Cash Equivalents (Continuing Ops) | $7.8 million | $2.9 million |
| Short-term Investments | $4.8 million | $0 |
| Net Cash Used in Operating Activities | $(19.8 million) | $(16.4 million) |
Note: The company reported no revenue from product sales. Discontinued operations relate to SEED Therapeutics Inc., which was reclassified in 2025 following a divestiture plan.
Material Changes vs. Prior Period
- Net Loss Reduction: Total net loss decreased by approximately 15% to $14.2 million in 2025 from $16.7 million in 2024, driven largely by a $7.0 million gain on the sale of subsidiary interests (SEED) in discontinued operations.
- Operating Expenses: Research and Development (R&D) expenses increased 66% to $4.4 million due to expanded drug manufacturing, data management for NSCLC studies, and regulatory costs. General and Administrative (G&A) expenses decreased 25% to $4.6 million due to reduced headcount and lower professional service fees.
- Liquidity: Cash and cash equivalents from continuing operations increased significantly to $7.8 million from $2.9 million, supported by net cash provided by investing activities ($10.8 million) primarily from the maturity of time deposits and proceeds from the sale of SEED interests.
- Discontinued Operations: SEED Therapeutics Inc. operations were reclassified as discontinued operations. The company recorded a gain of $7.0 million on the first closing of the sale of SEED preferred shares in February 2025.
Guidance, Outlook, and Risks
Outlook and Strategy: BeyondSpring plans to file a New Drug Application (NDA) with China's National Medical Products Administration (NMPA) for Plinabulin in second- and third-line non-small cell lung cancer (NSCLC) as soon as possible, following positive Phase 3 (DUBLIN-3) results. The company intends to initiate a confirmatory global Phase 3 study for NSCLC patients who progressed on prior immune checkpoint inhibitors. In the U.S. and rest of the world, the company plans to seek a co-development and commercialization partner.
Key Risks and Contingencies:
- Regulatory Hurdles: The FDA issued a Complete Response Letter in November 2021 regarding the NDA for Plinabulin in combination with G-CSF for chemotherapy-induced neutropenia (CIN), citing insufficient robustness of the single registrational trial. The company withdrew the NDA submission from the NMPA for this indication in March 2023.
- Liquidity Needs: The company anticipates continuing to incur significant operating losses and negative cash flows. It will require additional financing to fund clinical trials, regulatory filings, and commercialization efforts. There is no assurance that capital will be available on acceptable terms.
- SEED Divestiture: The company is in the process of selling its remaining interest in SEED Therapeutics Inc. in two additional closings expected in 2026. Upon the second closing, the company will lose controlling interest in SEED.
- Geopolitical and Regulatory Risks: Operations in China are subject to evolving regulations regarding data security, human genetic resources, and foreign investment. Tensions between the U.S. and China could impact clinical trials and supply chains.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.8 million cash balance to fund operations through the next 12 months given the $19.8 million annual operating cash burn.
- SEED Transaction Timeline: Monitor the status of the second and third closings of the SEED share sale scheduled for 2026, which will impact consolidated financials and control.
- NDA Filing Status: Confirm the timeline and regulatory feedback regarding the planned NDA filing with the NMPA for Plinabulin in NSCLC.
- Partnership Progress: Track progress in securing a U.S. commercialization partner for Plinabulin, as the company lacks internal sales capabilities.
- Regulatory Compliance: Review compliance with evolving Chinese data security and human genetic resource regulations, which could impact clinical trial data transfer.